Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinson’s Disease or Post-Stroke
Toxins · 2023
DOI: 10.3390/toxins15020166 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxins, 2023. Verfasst von Ju-Chuan Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung 407, Taiwan. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Parkinson Disease, Botulinum Toxins, Type A, Urinary Incontinence. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the Republic of China, Chang Gung Medical Foundation, Chang Gung Memorial Hospital.
Themen: Schlaganfall
Abstract (Originalsprache)
Botulinum toxin A (BoNT-A) paralyzes muscle by blocking acetylcholine release at the synaptic junction. BoNT-A has shown its therapeutic effects in neurological disorders such as Parkinson’s disease (PD) and post-stroke spasticity. A high proportion of patients with PD and post-stroke develop neurogenic detrusor overactivity (nDO) and then develop urinary incontinence and overactive bladder (OAB) symptoms. This study aimed to disclose the safety and efficacy of BoNT-A injection in treating bladder and voiding dysfunction in PD and post-stroke patients by reviewing the current evidence. At present, intradetrusor injection of BoNT-A is a Food and Drug Administration (FDA)-approved third-line therapy for nDO and idiopathic OAB. Although intradetrusor injection of onaBoNT-A 200 U is already approved for nDO treatment, most researchers would like to manage PD and post-stroke patients by using onaBoNT-A 100 U intradetrusor injection to achieve long-term efficacy and reduce adverse effects. However, in contrast to its inclusion in the International Continence Society guidelines for PD treatment, the clinical use of BoNT-A for post-stroke patients is limited to experimental use due to the development of urinary retention in about one-fifth of patients. For treating urethral pseudodyssynergia, half of patients may respond to onaBoNT-A 100 U urethral injection. However, refinement is needed to reduce unwanted urinary incontinence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung 407, Taiwan.
- Department of Urology, An Nan Hospital, China Medical University, Tainan City 833, Taiwan.
- Division of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 807, Taiwan.
- Center for Shock Wave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 807, Taiwan.
ORCID-Profile: Ju-Chuan Hu, Wei-Chia Lee, Yao-Chi Chuang
Förderung
- Ministry of Science and Technology of the Republic of China
- Chang Gung Medical Foundation
- Chang Gung Memorial Hospital
Zitieren
APA
Hu, J. C., Hsu, L. N., Lee, W. C., Chuang, Y. C., & Wang, H. J. (2023). Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinson’s Disease or Post-Stroke. Toxins. https://doi.org/10.3390/toxins15020166
Vancouver
Hu JC, Hsu LN, Lee WC, Chuang YC, Wang HJ. Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinson’s Disease or Post-Stroke. Toxins. 2023. doi:10.3390/toxins15020166
BibTeX
@article{Hu2023,
author = {Hu, Ju-Chuan and Hsu, Lin-Nei and Lee, Wei-Chia and Chuang, Yao-Chi and Wang, Hung-Jen},
title = {Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinson’s Disease or Post-Stroke},
journal = {Toxins},
year = {2023},
doi = {10.3390/toxins15020166}
}
EUVIMED